Staar surgical board of directors reiterates unanimous recommendation that staar stockholders vote “for” the alcon merger agreement on white proxy card

Lake forest, calif.--(business wire)--staar surgical company (nasdaq: staa) (“staar”), the global leader in phakic iols with the evo family of implantable collamer® lenses (evo icl™) for vision correction, today provided the following statement in response to a report issued by glass, lewis & co., llc (“glass lewis”) related to staar's pending merger with alcon (six/nyse: alc): the staar board of directors and management team strongly disagree with the recommendation issued by glass lewis.
ALC Ratings Summary
ALC Quant Ranking